RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kazuto Nishio, Kazuko Sakai, Takashi Seto, Makoto Nishio, Edward B. Garon, Martin Reck, Koichi Goto, Terufumi Kato, Yoichi Nakanishi, Toshiaki Takahashi, Nobuyuki Yamamoto, Katsuyuki Kiura, Yuichiro Ohe, Tomohide Tamura, Carla M Visseren-Grul, Rebecca R. Hozak, Sameera R. Wijayawardana, Sotaro Enatsu, Kazuhiko Nakagawa
Institutions: Kindai University, National Hospital Organization Kyushu Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, University of California, Los Angeles, German Center for Lung Research, National Cancer Center Hospital East, Kanagawa Cancer Center, Kitakyushu City Hospital Organization, Shizuoka Cancer Center, Wakayama Medical University, Okayama University, Okayama University Hospital, National Cancer Center Hospital, St. Luke's International Hospital, Eli Lilly (United States), Eli Lilly (Japan), Kindai University Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W3032754491